R. Lleonart-Bellfill

A pilot experience using a one-bag intravenous rapid desensitization protocol for chemotherapeutics and biologics in a cohort of patients with access to a delabeling pathway.

R. Madrigal-Burgaleta, P. Vazquez-Revuelta, R. Lleonart-Bellfill, 2022, Journal of investigational allergology & clinical immunology.

Medical algorithm: Diagnosis and treatment of hypersensitivity reactions to cancer chemotherapy

E. Álvarez-Cuesta, R. Madrigal-Burgaleta, F. R. Ali, 2021, Allergy.

Delabeling Patients from Chemotherapy and Biologics Allergy: Implementing Drug Provocation Testing.

R. Madrigal-Burgaleta, P. Vazquez-Revuelta, J. Martí-Garrido, 2020, The journal of allergy and clinical immunology. In practice.

Pilot experience using drug provocation testing for the study of hypersensitivity to chemotherapy and biological agents.

R. Madrigal-Burgaleta, P. Vazquez-Revuelta, J. Martí-Garrido, 2020, Journal of investigational allergology & clinical immunology.

Are antihistamines still used during omalizumab treatment for chronic spontaneous urticaria?

M. Guilarte, A. Sala-Cunill, V. Expósito-Serrano, 2022, European Journal of Dermatology.

Expert review and consensus on the t2t management of hereditary angioedema: from the scientific evidence to clinical practice.

M. Pedrosa, M. Guilarte, T. Caballero, 2023, Journal of investigational allergology & clinical immunology.